866-997-4948(US-Canada Toll Free)

Mild Psoriasis - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Apr 2015

Category :

Psoriasis

No. of Pages : 48


Global Markets Directs, Mild Psoriasis Pipeline Review, H1 2015, provides an overview of the Mild Psoriasiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Mild Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild Psoriasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mild Psoriasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Mild Psoriasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Mild Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Mild Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Mild Psoriasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Mild Psoriasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Mild Psoriasis Overview 6
Therapeutics Development 7
Pipeline Products for Mild Psoriasis - Overview 7
Pipeline Products for Mild Psoriasis - Comparative Analysis 8
Mild Psoriasis - Therapeutics under Development by Companies 9
Mild Psoriasis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Mild Psoriasis - Products under Development by Companies 12
Mild Psoriasis - Companies Involved in Therapeutics Development 13
Almirall, S.A. 13
Avexxin AS 14
Convoy Therapeutics, Inc. 15
Delenex Therapeutics AG 16
GlycoMar Limited 17
OPKO Health, Inc. 18
Soligenix, Inc. 19
UCB S.A. 20
Mild Psoriasis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AKP-11 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AVX-001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
cyclosporine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DLX-105 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DLX-3003 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GLY-2028 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
lunacalcipol - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SGX-301 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tazarotene - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
UCB-5857 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Mild Psoriasis - Recent Pipeline Updates 43
Mild Psoriasis - Dormant Projects 45
Mild Psoriasis - Discontinued Products 46

Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Table


Number of Products under Development for Mild Psoriasis, H1 2015 7
Number of Products under Development for Mild Psoriasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Development, H1 2015 11
Products under Development by Companies, H1 2015 12
Mild Psoriasis - Pipeline by Almirall, S.A., H1 2015 13
Mild Psoriasis - Pipeline by Avexxin AS, H1 2015 14
Mild Psoriasis - Pipeline by Convoy Therapeutics, Inc., H1 2015 15
Mild Psoriasis - Pipeline by Delenex Therapeutics AG, H1 2015 16
Mild Psoriasis - Pipeline by GlycoMar Limited, H1 2015 17
Mild Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 18
Mild Psoriasis - Pipeline by Soligenix, Inc., H1 2015 19
Mild Psoriasis - Pipeline by UCB S.A., H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Mild Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 43
Mild Psoriasis - Dormant Projects, H1 2015 45
Mild Psoriasis - Discontinued Products, H1 2015 46

List of Chart


Number of Products under Development for Mild Psoriasis, H1 2015 7
Number of Products under Development for Mild Psoriasis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 11
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 22
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *